On Friday, Hyperfine Inc (NASDAQ: HYPR) opened lower -11.62% from the last session, before settling in for the closing price of $1.98. Price fluctuations for HYPR have ranged from $0.53 to $2.19 over the past 52 weeks.
During the last 5-year period, the sales growth of Healthcare Sector giant was 11.81%. Company’s average yearly earnings per share was noted 21.43% at the time writing. With a float of $58.00 million, this company’s outstanding shares have now reached $63.53 million.
Hyperfine Inc (HYPR) Insider Activity
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Hyperfine Inc is 26.19%, while institutional ownership is 10.38%. The most recent insider transaction that took place on Aug 18 ’25, was worth 1,531. In this transaction Chief Operating Officer of this company sold 1,151 shares at a rate of $1.33, taking the stock ownership to the 381,062 shares. Before that another transaction happened on May 16 ’25, when Company’s Chief Operating Officer sold 2,776 for $0.58, making the entire transaction worth $1,610. This insider now owns 82,213 shares in total.
Hyperfine Inc (HYPR) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.14 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.14) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.43% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.36% during the next five years compared to 11.81% growth over the previous five years of trading.
Hyperfine Inc (NASDAQ: HYPR) Trading Performance Indicators
Check out the current performance indicators for Hyperfine Inc (HYPR). In the past quarter, the stock posted a quick ratio of 4.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.53, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.42 in one year’s time.
